Editas Medicine, Inc. (EDIT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:46AM EDT. Market open.
| Previous close | 5.55 |
| Open | 5.52 |
| Bid | 5.41 x 600 |
| Ask | 5.46 x 100 |
| Day's range | 5.41 - 5.68 |
| 52-week range | 5.41 - 11.91 |
| Volume | |
| Avg. volume | 1,915,169 |
| Market cap | 447.085M |
| Beta (5Y monthly) | 2.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.02 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.86 |
ZacksWhy Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GuruFocus.comInsider Sells Shares of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
Simply Wall St.Editas Medicine, Inc. (NASDAQ:EDIT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest full-year results and things are looking bullish...
© 2024 Yahoo. All rights reserved.